Physician profile
David Beckett
NPI 1841794880
$4,753.68
in general payments reported to CMS, 2019-2025
25 companies · $973 in 2025
The $973 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $437 · 2021: $845 · 2022: $930 · 2023: $336 · 2024: $976 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.86 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $622.56 | 2021-2025 | Rocklatan, Tryptyr, Argos |
| Allergan, INC. | $572.16 | 2019-2022 | |
| Abbvie INC. | $503.56 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $447.82 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $380.28 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $355.41 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $343.14 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $262.27 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $235.58 | 2020-2022 | |
| Dompe US, INC. | $154.16 | 2021-2025 | Oxervate |
| Glaukos Corporation | $149.56 | 2022 | |
| Harrow Eye, LLC | $145.71 | 2024-2025 | Vevye, Iheezo, Triesence |
| Aerie Pharmaceuticals, INC. | $133.76 | 2021 | |
| Mallinckrodt Hospital Products INC. | $123.75 | 2024-2025 | Acthar |
| Coopervision INC. | $63.89 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $51.44 | 2020-2021 | |
| Sight Sciences, INC. | $47.97 | 2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $30.95 | 2023 | Tecnis Iol |
| Regeneron Healthcare Solutions, INC. | $28.48 | 2021 | |
| Thea Pharma INC. | $23.81 | 2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $18.00 | 2021 | |
| Visioneering Technologies, INC. | $17.06 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $15.35 | 2022 | |
| Biotissue Holdings INC. | $14.00 | 2025 | |
| Ivantis, INC | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.